What: Phase 3B/4 randomized safety endpoint study of 2 doses of Tofacitinib in comparison to a tumor necrosis factor (TNF) inhibitor in subjects with Rheumatoid Arhritis.
Who: Male & Females 50 or older
Duration: 5 years /22 visits
What: Phase 3B/4 randomized safety endpoint study of 2 doses of Tofacitinib in comparison to a tumor necrosis factor (TNF) inhibitor in subjects with Rheumatoid Arhritis.
Who: Male & Females 50 or older
Duration: 5 years /22 visits